Experience of using different schemes of eradication therapy for Helicobacter pylori infection and their effectiveness in Ukraine

Background. The resistance of Helicobacter pylori (H.pylori) to antibacterial drugs has increased in recent years. This is primarily due to the unwarranted use of antibiotics, as demonstra­ted by the recent COVID-19 pandemic. The choice of the optimal regimen and duration of treatment are current issues today. The aim: retrospective study on the effectiveness of 14-day H.pylori eradication regimens used in 2022–2023 and comparison of their effectiveness and safety with those of 10-day regimens used in 2020–2021 in Ukraine. Materials and methods. The data of 242 patients (123 men and 119 women) aged 18 to 65 years with chronic gastritis, peptic ulcer of the duodenum and stomach associated with H.pylori were analyzed retrospectively. All patients were treated with standard regimens according to the Maastricht V and VI Consensus. H.pylori infection was confirmed by a rapid urease test, determination of fecal antigen and histologically. Results. As a result of the study, it was found that 10-day regimens with triple therapy had an efficiency of 80–81 %. The effectiveness of a 14-day triple therapy with esomeprazole and lansoprazole was significantly higher compared to a 10-day regimen, 85 and 86 %, respectively (p